We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+4.37%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$338M
AUM Growth
-$1.49B
(-81%)
Cap. Flow
-$1.49B
Cap. Flow
% of AUM
-440.09%
Top 10 Holdings %
Top 10 Hldgs %
50.11%
Holding
82
New
26
Increased
20
Reduced
13
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$21.3M |
| 2 |
Integra LifeSciences
IART
|
+$13.4M |
| 3 |
AbbVie
ABBV
|
+$12.8M |
| 4 |
AdaptHealth
AHCO
|
+$9.39M |
| 5 |
Encompass Health
EHC
|
+$8.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$6.95M |
| 2 |
ICU Medical
ICUI
|
+$6.55M |
| 3 |
Labcorp
LH
|
+$6.3M |
| 4 |
Centene
CNC
|
+$5.94M |
| 5 |
SI-BONE Inc
SIBN
|
+$5.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.24% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $30.8M | 9.1% |
91,300
+13,700
| +18% | +$4.54M |
|
|
2
Bristol-Myers Squibb
BMY
$133B
| $23.5M | 6.96% |
390,156
+354,047
| +980% | +$21.3M |
|
|
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $20.5M | 6.07% |
1,754,465
+357,670
| +26% | +$4.75M |
|
|
4
Encompass Health
EHC
$11B
| $17.9M | 5.31% |
347,064
+169,582
| +96% | +$8.7M |
|
|
5
AbbVie
ABBV
$443B
| $17.4M | 5.15% |
198,921
+136,306
| +218% | +$12.8M |
|
|
6
Integra LifeSciences
IART
$1.29B
| $13.3M | 3.93% |
+281,608
| New | +$13.4M |
|
7
PUT
iShares Russell 2000 ETF
IWM
$79.8B
| $12.1M | 3.57% |
+80,500
| New | +$12.1M |
|
8
Cigna
CI
$73.7B
| $11.4M | 3.38% |
67,461
+31,339
| +87% | +$5.52M |
|
|
9
AdaptHealth
AHCO
$1.47B
| $11.3M | 3.34% |
518,377
+447,377
| +630% | +$9.39M |
|
10
Johnson & Johnson
JNJ
$618B
| $11.2M | 3.3% |
74,979
-8,900
| -11% | -$1.32M |
|
|
11
SI-BONE Inc
SIBN
$788M
| $11M | 3.25% |
463,150
-280,230
| -38% | -$5.57M |
|
12
Zoetis
ZTS
$32.4B
| $7.77M | 2.3% |
46,960
-26,240
| -36% | -$4.03M |
|
13
Zimmer Biomet
ZBH
$18.2B
| $7.38M | 2.18% |
55,861
+8,442
| +18% | +$1.1M |
|
14
CONMED
CNMD
$1.39B
| $6.39M | 1.89% |
+81,205
| New | +$6.62M |
|
15
Ocular Therapeutix
OCUL
$1.79B
| $6.37M | 1.88% |
837,137
+81,807
| +11% | +$679K |
|
16
McKesson
MCK
$100B
| $6.02M | 1.78% |
40,419
+24,477
| +154% | +$3.72M |
|
|
SYNH
17
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $5.96M | 1.76% |
112,151
+57,574
| +105% | +$3.43M |
|
18
OrthoPediatrics
KIDS
$519M
| $5.82M | 1.72% |
+126,764
| New | +$5.88M |
|
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $5.79M | 1.71% |
+52,000
| New | +$5.83M |
|
|
TRIL
20
DELISTED
Trillium Therapeutics Inc.
TRIL
| $5.29M | 1.57% |
372,401
-305,422
| -45% | -$3.05M |
|
|
ESPR
21
DELISTED
Esperion Therapeutics
ESPR
| $5.05M | 1.49% |
135,901
-47,348
| -26% | -$1.88M |
|
22
Elevance Health
ELV
$81.5B
| $4.81M | 1.42% |
17,909
-12,119
| -40% | -$3.26M |
|
23
Sutro Biopharma
STRO
$401M
| $4.64M | 1.37% |
46,217
+30,616
| +196% | +$2.89M |
|
24
Insmed
INSM
$21.4B
| $4.64M | 1.37% |
144,313
+4,129
| +3% | +$119K |
|
|
MTEM
25
DELISTED
Molecular Templates, Inc.
MTEM
| $4.62M | 1.37% |
28,186
+12,865
| +84% | +$2.29M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Endurant Capital Management held 82 positions worth $338M, down 81% from $1.82B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Endurant Capital Management withdrew a net $1.49B in Q3 2020, closing 22 positions and reducing 13 holdings. Its most notable exit was Medtronic, an estimated $6.95M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 12% a quarter earlier, followed by Industrials.
Against the trend, Endurant Capital Management opened a new position in Integra LifeSciences worth $13.3M.
- Endurant Capital Management's largest Q3 2020 buy was Integra LifeSciences: 281,608 shares worth $13.3M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q3 2020, an estimated $21.3M increase.
- Endurant Capital Management's biggest Q3 2020 reduction was Centene, cutting an estimated $5.94M.
- Endurant Capital Management fully exited Medtronic in Q3 2020, selling an estimated $6.95M.
- Endurant Capital Management's ten largest holdings make up 50% of its $338M portfolio in Q3 2020.
- Endurant Capital Management opened 26 new positions and closed 22 in Q3 2020.
- Endurant Capital Management's portfolio value fell 81% quarter-over-quarter to $338M.
Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.